Related Experiment Video
Updated: May 5, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Hunting glioblastoma recurrence: glioma stem cells as retrospective targets
Sümeyra Mengüç Emir1, Birnur Sinem Karaoğlan1, Ramazan Kaşmer1
1Cancer Research Center, Research Institute for Health Sciences and Technologies (SABITA), İstanbul Medipol University, Istanbul, Türkiye.
Abstract:
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain malignancies in adults. Standard approaches, including surgical resection followed by adjuvant radio- and chemotherapy with temozolomide (TMZ), provide only transient control, as GBM frequently recurs due to its infiltrative nature and the presence of therapy-resistant subpopulations such as glioma stem cells (GSCs). GSCs, with their quiescent state and robust resistance mechanisms, evade conventional therapies, contributing significantly to relapse. Consequently, current treatment methods for GBM face significant limitations in effectively targeting GSCs. In this review, we emphasize the relationship between GBM recurrence and GSCs, discuss the current limitations, and provide future perspectives to overwhelm the challenges associated with targeting GSCs. Eliminating GSCs may suppress recurrence, achieve durable responses, and improve therapeutic outcomes for patients with GBM.
Insights
Glioblastoma recurrence is driven by therapy-resistant glioma stem cells (GSCs). Targeting these GSCs offers a promising strategy to improve glioblastoma treatment outcomes and achieve durable responses.
Area of Science:
- Neuro-oncology
- Cancer stem cell biology
- Glioblastoma multiforme (GBM) research
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis.
- Standard treatments (surgery, radiation, temozolomide) offer limited long-term efficacy due to tumor recurrence.
- Glioma stem cells (GSCs) are implicated in GBM's resistance to therapy and its frequent relapse.
Purpose of the Study:
- To review the critical role of GSCs in GBM recurrence.
- To discuss the limitations of current therapeutic strategies in targeting GSCs.
- To explore future perspectives for overcoming GSC-mediated treatment resistance.
Main Methods:
- Literature review focusing on GSC biology and GBM treatment resistance.
- Analysis of current therapeutic approaches and their impact on GSCs.
- Synthesis of existing research to identify challenges and opportunities.
Main Results:
- GSCs possess unique characteristics (quiescence, robust resistance mechanisms) that enable evasion of conventional therapies.
- The presence and persistence of GSCs are major contributors to GBM recurrence and treatment failure.
- Current treatments inadequately address the GSC population, highlighting a significant therapeutic gap.
Conclusions:
- Targeting GSCs is crucial for overcoming GBM recurrence and achieving durable clinical responses.
- Developing novel therapeutic strategies specifically aimed at eliminating GSCs is essential for improving patient outcomes.
- Further research into GSC biology and targeted therapies holds significant promise for advancing GBM treatment.
